A window into immunosuppressant immunoregulation: Recipient conversion to rapamycin increases potentially tolerogenic immune cells

Kidney International

Volumn 85, Issue 4, 2014, Pages 743-745

  Rosborough, Brian R ^a   Hackstein, Holger ^b,c   Turnquist, Heth R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN ILT3; PROTEIN ILT4; RAPAMYCIN; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; CD86 ANTIGEN; EVEROLIMUS; IMMUNOGLOBULIN LIKE TRANSCRIPT 3 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MAMMALIAN TARGET OF RAPAMYCIN; PROGRAMMED DEATH 1 LIGAND 1;

CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL POPULATION; CELL SPECIFICITY; DRUG EFFECT; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; KIDNEY TRANSPLANTATION; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; DENDRITIC CELL; DRUG EFFECTS; T LYMPHOCYTE; ANTIGEN PRESENTING CELL; CHRONIC ALLOGRAFT NEPHROPATHY; CYTOKINE PRODUCTION; IMMUNOMODULATION; KIDNEY GRAFT; LYMPHOCYTE DIFFERENTIATION; MYELOID DENDRITIC CELL; PROTEIN FUNCTION; SURVIVAL TIME;

DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; T-LYMPHOCYTES;

EID: 84897377702     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.420     Document Type: Note

References (10)

1. Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: Comparative analysis of two decades. Transplantation 2007; 84: 137-143.
2. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337.
3. Akimova T, Kamath BM, Goebel JW et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012; 12: 3449-3461.
4. Haidinger M, Poglitsch M, Geyeregger R et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185: 3919-3931.
5. Brouard S, Puig-Pey I, Lozano J-J et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant 2010; 10: 2604-2614.
6. Stallone G, Pontrelli P, Infante B et al. Rapamycin induces ILT3highILT4high dendritic cells promoting a new immunoregulatory pathway. Kidney Int 2014; 85: 888-897.
7. Wu J, Horuzsko A. Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells. Hum Immunol 2009; 70: 353-356.
8. Ochando JC, Homma C, Yang Y et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652-662.
9. Ristich V, Liang S, Zhang W et al. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005; 35: 1133-1142.
10. Wang C, Yi T, Qin L et al. Rapamycin-Treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest 2013; 123: 1677-1693.